PERMA FIX ENVIRONMENTAL SERVICES INC
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Notes to Condensed Consolidated Financial Statements
March 31, 2024
Reference is made herein to the notes to consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023.
1. Basis of Presentation
The condensed consolidated financial statements included herein have been prepared by the Company (which may be referred to as we, us or our), without an audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the “Commission”). Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations, although the Company believes the disclosures which are made are adequate to make the information presented not misleading. Further, the condensed consolidated financial statements reflect, in the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position and results of operations as of and for the periods indicated. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of results to be expected for the fiscal year ending December 31, 2024.
These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K as of and for the year ended December 31, 2023.
The condensed consolidated financial statements include the accounts of our wholly-owned subsidiaries.
Financial Position and Liquidity
The Company’s results of operations in the first quarter of 2024 were impacted by accelerated investments and several events, which included the following:
Accelerated investments in research and development (“R&D”) on our new technology to treat Per- and Polyfluorinated Substances (“PFAS”);
Reduced activities by our customers due to poor weather conditions, which resulted in the closure of two of our facilities for a week, including delays in shipments to support backlog;
Continuing Resolution impacts due to the inability of Congress to pass a Federal Budget through late March 2024, which contributed to delays in procurements, project starts and waste shipment, due to uncertain budget projections by our government clients;
Completion of two large projects in the Services Segment that were not replaced by new project starts due to delays in mobilization activities until late April; and
All three primary treatment facilities realized outages in March which impacted revenue as the Company utilized the aforementioned slowdowns for equipment replacement and repairs, program enhancements, and testing to support permit expansion and broader market penetration.
The Company believes that most of these accelerated investments and unanticipated impacts should have limited duration effects to its financial performance. The Company expects that the second quarter will not include material continued impact from these activities. With the passage of the Federal Budget in late March 2024 and improved weather conditions, the Company has begun to see steady improvements in waste receipts, project starts that were delayed and increased procurement activities. The Company’s waste treatment backlog stands at approximately $10,580,000 as of March 31, 2024, an increase of approximately $1,878,000 from the December 31, 2023, balance of $8,702,000.
The Company’s cash flow requirements for the next twelve months will consist primarily of general working capital needs, scheduled principal payments on its debt obligations, remediation projects, and planned capital expenditures which include its PFAS technology. The Company plans to fund these requirements from its operations, credit facility availability, cash on hand (which will include, when received, cash from outstanding receivables due to our Perma-Fix Canada, Inc. subsidiary from a certain customer - See “Note 9 – Commitments and Contingencies - Perma-Fix Canada, Inc. (“PF Canada”)” for a discussion of this outstanding receivables) and possible other methods. The Company’s ability to utilize its credit facility from its lender is subject to meeting our quarterly financial covenant requirements, among other things. The Company continues to explore all sources of increasing its capital and/or liquidity and to improve its revenue and working capital, including, but not limited to entering into equity transactions. There are no assurances that the Company will be successful in increasing its liquidity through its efforts. The Company is continually reviewing operating costs and reviewing the possibility of further reducing operating costs and non-essential expenditures to bring them in line with revenue levels, when necessary. The Company believes that its cash flows from operations, its available liquidity from its credit facility, and its cash on hand (which will include, when received, cash from the outstanding Canadian receivables noted above) should be sufficient to fund our operations for the next twelve months.
2. Summary of Significant Accounting Policies
Our accounting policies are as set forth in the notes to the December 31, 2023, consolidated financial statements referred to above.
Recently Issued Accounting Standards – Not Yet Adopted
In August 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-05, “Business Combinations—Joint Venture Formations (Subtopic 805-60): Recognition and Initial Measurement.” ASU 2023-05 applies to the formation of a “joint venture” or a “corporate joint venture” and requires a joint venture to initially measure all contributions received upon its formation at fair value. The guidance does not impact accounting by the venturers. The new guidance is applicable to joint venture entities with a formation date on or after January 1, 2025 on a prospective basis. The Company is currently evaluating the impact of this ASU on its consolidated financial statements.
In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,” which expands reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the chief operating decision maker (“CODM”) and included within each reported measure of a segment’s profit or loss. The ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment’s profit or loss in assessing segment performance and deciding how to allocate resources. Additionally, ASU 2023-07 requires all segment profit or loss and assets disclosures to be provided on an annual and interim basis. The amendments in this ASU are required to be adopted for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 with early adoption permitted, and should be applied on a retrospective basis. ASU 2023-07 will be effective for the Company’s financial statements for the year ended December 31, 2024. This ASU will not have impact on the Company’s consolidated financial condition or results of operations. The Company is evaluating the impact to the related segment reporting disclosures.
In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures,” which modifies the rules on income tax disclosures to require entities to disclose (1) specific categories in the rate reconciliation, (2) the income or loss from continuing operations before income tax expense or benefit (separated between domestic and foreign) and (3) income tax expense or benefit from continuing operations (separated by federal, state and foreign). ASU 2023-09 also requires entities to disclose their income tax payments to international, federal, state and local jurisdictions, among other changes. The guidance is effective for annual periods beginning after December 15, 2024. ASU 2023-09 should be applied on a prospective basis, but retrospective application is permitted. This ASU will not have impact on the Company’s consolidated financial condition or results of operations. The Company is evaluating the impact to its income taxes reporting disclosures.
3. Revenue ****
Disaggregation of Revenue
In general, the Company’s business segmentation is aligned according to the nature and economic characteristics of our services and provides meaningful disaggregation of each business segment’s results of operations. The nature of the Company’s performance obligations within our Treatment and Services Segments results in the recognition of our revenue primarily over time. The following tables present further disaggregation of our revenues by different categories for our Services and Treatment Segments:
Revenue by Contract Type
| (In thousands) · Three Months Ended · Three Months Ended | ||||||
|---|---|---|---|---|---|---|
| March 31, 2024 | March 31, 2023 | |||||
| Treatment | Services | Total | Treatment | Services | Total | |
| Fixed price | $8,709 | $4,314 | $13,023 | $9,594 | $8,647 | $18,241 |
| Time and materials | — | 594 | 594 | — | 1,866 | 1,866 |
| Total | $8,709 | $4,908 | $13,617 | $9,594 | $10,513 | $20,107 |
Revenue by generator
| (In thousands) · Three Months Ended · Three Months Ended | ||||||
|---|---|---|---|---|---|---|
| March 31, 2024 | March 31, 2023 | |||||
| Treatment | Services | Total | Treatment | Services | Total | |
| Domestic government | $5,761 | $4,303 | $10,064 | $7,257 | $9,718 | $16,975 |
| Domestic commercial | 2,501 | 504 | 3,005 | 2,206 | 597 | 2,803 |
| Foreign government | — | 79 | 79 | 95 | 177 | 272 |
| Foreign commercial | 447 | 22 | 469 | 36 | 21 | 57 |
| Total | $8,709 | $4,908 | $13,617 | $9,594 | $10,513 | $20,107 |
Contract Balances
The timing of revenue recognition and billings results in unbilled receivables (contract assets). The Company’s contract liabilities consist of deferred revenues which represent advance payment from customers in advance of the completion of our performance obligation. The following table represents changes in our contract asset and contract liabilities balances:
| Year-to-date · Year-to-date | ||||
|---|---|---|---|---|
| (In thousands) | March 31, 2024 | December 31, 2023 | Change ($) | Change (%) |
| Contract assets | ||||
| Unbilled receivables - current | $8,797 | $8,432 | $365 | 4.3% |
| Contract liabilities | ||||
| Deferred revenue | $7,295 | $6,815 | $480 | 7.0% |
During the three months ended March 31, 2024, and 2023, the Company recognized revenue of $3,165,000 and $3,494,000, respectively, related to untreated waste that was in the Company’s control as of the beginning of each respective year. Revenue recognized in each period relates to performance obligations satisfied within the respective period.
Remaining Performance Obligations
The Company applies the practical expedient in ASC 606-10-50-14 and does not disclose information about remaining performance obligations that have original expected durations of one year or less.
Within our Services Segment, there are service contracts which provide that the Company has a right to consideration from a customer in an amount that corresponds directly with the value to the customer of our performance completed to date. For those contracts, the Company has utilized the practical expedient in ASC 606-10-55-18, which allows the Company to recognize revenue in the amount for which we have the right to invoice; accordingly, the Company does not disclose the value of remaining performance obligations for those contracts.
The Company’s contracts and subcontracts relating to activities at governmental sites generally allow for termination for convenience at any time at the government’s option without payment of a substantial penalty. The Company does not disclose remaining performance obligations on these contracts.
4. Leases ****
At the inception of an arrangement, the Company determines if an arrangement is, or contains, a lease based on facts and circumstances present in that arrangement. Lease classifications, recognition, and measurement are then determined at the lease commencement date.
The Company’s operating lease right-of-use (“ROU”) assets and operating lease liabilities include primarily leases for office and warehouse spaces used to conduct our business. The Company’s operating leases also include a building with land utilized for our waste treatment operations which includes a purchase option. Finance leases consist primarily of processing and transport equipment used by our facilities’ operations.
The components of lease cost for the Company’s leases were as follows (in thousands):
| Three Months Ended | ||
|---|---|---|
| March 31, | ||
| 2024 | 2023 | |
| Operating Lease: | ||
| Lease cost | $143 | $156 |
| Finance Leases: | ||
| Amortization of ROU assets | 65 | 38 |
| Interst on lease liablity | 22 | 6 |
| Finance lease | 87 | 44 |
| Total lease cost | $230 | $200 |
The weighted average remaining lease term and the weighted average discount rate for operating and finance leases at March 31, 2024 were:
| Operating Leases | Finance Leases | |
|---|---|---|
| Weighted average remaining lease terms (years) | 5.4 | 4.3 |
| Weighted average discount rate | 7.6% | 8.8% |
The weighted average remaining lease term and the weighted average discount rate for operating and finance leases at March 31, 2023 were:
| Operating Leases | Finance Leases | |
|---|---|---|
| Weighted average remaining lease terms (years) | 6.1 | 3.0 |
| Weighted average discount rate | 7.8% | 5.5% |
The following table reconciles the undiscounted cash flows for the operating and finance leases at March 31, 2024, to the operating and finance lease liabilities recorded on the balance sheet (in thousands):
| Operating Leases · Finance Leases | ||
|---|---|---|
| 2024 | $372 | $275 |
| 2025 | 433 | 345 |
| 2026 | 416 | 192 |
| 2027 | 406 | 157 |
| 2028 | 383 | 134 |
| 2029 and thereafter | 366 | 102 |
| Total undiscounted lease payments | 2,376 | 1,205 |
| Less: Imputed interest | (436) | (212) |
| Present value of lease payments | $1,940 | $993 |
| Current portion of operating lease obligations | $346 | $— |
| Long-term operating lease obligations, less current portion | $1,594 | $— |
| Current portion of finance lease obligations | $— | $287 |
| Long-term finance lease obligations, less current portion | $— | $706 |
Supplemental cash flow and other information related to our leases were as follows (in thousands):
| Three Months Ended | ||
|---|---|---|
| March 31, | ||
| 2024 | 2023 | |
| Cash paid for amounts included in the measurement of lease liabilities: | ||
| Operating cash flow from operating leases | $147 | $144 |
| Operating cash flow from finance leases | $22 | $6 |
| Financing cash flow from finance leases | $75 | $41 |
| ROU assets obtained in exchange for lease obligations for: | ||
| Finance liabilities | $— | $50 |
5. Intangible Assets
The following table summarizes information relating to the Company’s definite-lived intangible assets:
| March 31, 2024 · December 31, 2023 | |||||||
|---|---|---|---|---|---|---|---|
| Weighted Average · Gross · Net · Gross · Net | |||||||
| Amortization Period | Carrying | Accumulated | Carrying | Carrying | Accumulated | Carrying | |
| (Years) | Amount | Amortization | Amount | Amount | Amortization | Amount | |
| Other Intangibles (amount in thousands) | |||||||
| Patents | 8.3 | $710 | $(390) | $320 | $710 | $(387) | $323 |
| Software | 3 | 673 | (551) | 122 | 667 | (529) | 138 |
| Total | $1,383 | $(941) | $442 | $1,377 | $(916) | $461 | |
The intangible assets noted above are amortized on a straight-line basis over their useful lives.
The following table summarizes the expected amortization over the next five years for our definite-lived intangible assets:
| Amount | |
|---|---|
| Year | (In thousands) |
| 2024 (Remaining) | $58 |
| 2025 | 45 |
| 2026 | 40 |
| 2027 | 22 |
| 2028 | 13 |
Amortization expenses relating to the definite-lived intangible assets as discussed above were $25,000 and $55,000 for the three months ended March 31, 2024, and 2023, respectively.
6. Capital Stock, Stock Plans, Warrants and Stock Based Compensation
The Company has certain stock option plans under which it may award incentive stock options (“ISOs”) and/or non-qualified stock options (“NQSOs”) to employees, officers, outside directors, and outside consultants.
On January 18, 2024, the Company granted ISOs to certain employees under the 2017 Stock Option Plan (“2017 Plan”), for the purchase of up to an aggregate of 45,000 shares of the Company’s common stock, par value $.001 (the “Common Stock”). Each ISO granted is for a contractual term ofsix years withone-fifth vesting annually over a five-year period. The exercise price of the ISO is $7.75 per share, which was equal to the fair market value of the Company’s Common Stock on the date of grant.
The following table summarizes stock-based compensation recognized for the three months ended March 31, 2024, and 2023 for our employee and director stock options.
| Three Months Ended | ||
|---|---|---|
| Stock Options | March 31, | |
| 2024 | 2023 | |
| Employee Stock Options | $91,000 | $86,000 |
| Director Stock Options | 61,000 | 32,000 |
| Total | $152,000 | $118,000 |
At March 31, 2024, the Company had approximately $1,823,000 of total unrecognized compensation costs related to unvested options for employee and directors. The weighted average period over which the unrecognized compensation costs are expected to be recognized is approximately 3.2 years.
The summary of the Company’s total Stock Option Plans as of March 31, 2024 and March 31, 2023, and changes during the periods then ended, are presented below. The Company’s Plans consist of the 2017 Plan and the 2003 Outside Directors Stock Plan (the “2003 Plan”):
| Shares | Weighted Average Exercise Price | Weighted Average Remaining Contractual Term (years) | Aggregate Intrinsic Value (4) | |
|---|---|---|---|---|
| Options outstanding January 1, 2024 | 994,500 | $5.57 | - | |
| Granted | 45,000 | $7.75 | ||
| Exercised | (43,500) | $5.61 | $212,410 | |
| Forfeited | (11,000) | $7.01 | ||
| Options outstanding end of period (1) | 985,000 | $5.66 | 4.8 | $6,139,346 |
| Options exercisable at March 31, 2024(2) | 350,300 | $5.06 | 3.8 | $2,391,576 |
| Shares | Weighted Average Exercise Price | Weighted Average Remaining Contractual Term (years) | Aggregate Intrinsic Value (4) | |
|---|---|---|---|---|
| Options outstanding January 1, 2023 | 1,018,400 | $5.02 | - | |
| Granted | 295,000 | $3.95 | ||
| Exercised | (44,400) | $3.56 | $370,196 | |
| Forfeited/expired | (4,500) | $3.90 | ||
| Options outstanding end of period (3) | 1,264,500 | $4.83 | 4.2 | $8,791,279 |
| Options exercisable at March 31, 2023(3) | 499,500 | $4.30 | 2.3 | $6,047,029 |
| (1) | Options with exercise prices ranging from $3.15 to $9.81 |
| (2) | Options with exercise prices ranging from $3.15 to $7.50 |
| (3) | Options with exercise prices ranging from $2.79 to $7.50 |
| (4) | The intrinsic value of a stock option is the amount by which the market value of the underlying stock exceeds the exercise price of the option. |
During the three months ended March 31, 2024, the Company issued a total of 14,963 shares of its Common Stock under the 2003 Plan to its outside directors as compensation for serving on our Board of Directors (the “Board”). The Company recorded approximately $118,000 in compensation expenses (included in selling, general and administration (“SG&A”) expenses) in connection with the issuance of shares of its Common Stock to outside directors.
During the three months ended March 31, 2024, the Company issued an aggregate 12,916 shares of its Common Stock from cashless exercises of options for the purchase of 25,000 shares of the Company’s Common Stock ranging from $3.15 per share to $7.005 per share. Additionally, the Company issued 18,500 shares of its Common Stock from the cash exercises of options for the purchase of 18,500 shares of the Company’s Common Stock, at exercise prices ranging from $3.95 per share to $7.005 per share, resulting in proceeds of approximately $104,000.
In connection with a $2,500,000 loan that the Company received from Mr. Robert Ferguson (the “Ferguson Loan”) on April 1, 2019, the Company issued a warrant to Mr. Ferguson (the “Ferguson Warrant”) for the purchase of up to 60,000 shares of our Common Stock at an exercise price of $3.51 per share. The Ferguson Loan was paid in full in December 2020. Upon Mr. Ferguson’s death, the Ferguson Warrant was transferred equally to Mr. Ferguson’s two heirs with each holding a Warrant for the purchase of up to 30,000 shares of the Company’s Common Stock, as permitted under the Ferguson Warrant. One of the Warrants was exercised by Mr. Ferguson’s heir in 2023. On March, 22, 2024, the remaining Warrant was exercised by Mr. Ferguson’s heir for the purchase of 30,000 shares of the Company’s Common Stock, resulting in proceeds received by the Company of approximately $105,000.
7. Loss Per Share
Basic loss per share is calculated based on the weighted-average number of outstanding common shares during the applicable period. Diluted loss per share is based on the weighted-average number of outstanding common shares plus the weighted-average number of potential outstanding common shares. In periods where they are anti-dilutive, such amounts are excluded from the calculations of dilutive loss earnings per shares. The following table reconciles the loss and average share amounts used to compute both basic and diluted loss per share:
| Three Months Ended | ||
|---|---|---|
| (Unaudited) | ||
| March 31, | ||
| (Amounts in Thousands, Except for Per Share Amounts) | 2024 | 2023 |
| Loss per common share from continuing operations | ||
| Loss from continuing operations, net of taxes | $(3,458) | $(318) |
| Basic and diluted loss per share | $(.25) | $(.02) |
| Loss per common share from discontinued operations, net of taxes | ||
| Loss from discontinued operations, net of taxes | $(102) | $(93) |
| Basic and diluted loss per share | $(.01) | $(.01) |
| Net loss per common share | ||
| Net loss | $(3,560) | $(411) |
| Basic and diluted loss per share | $(.26) | $(.03) |
| Weighted average shares outstanding: | ||
| Basic weighted average shares outstanding | 13,676 | 13,358 |
| Add: dilutive effect of stock options | — | — |
| Diluted weighted average shares outstanding | 13,676 | 13,358 |
| Potential shares excluded from above weighted average share calculations due to their anti-dilutive effect include: | ||
| Stock options | 75 | 335 |
8. Long Term Debt
Long-term debt consists of the following as of March 31, 2024, and December 31, 2023:
| (Amounts in Thousands) · March 31, 2024 · December 31, 2023 | ||||
|---|---|---|---|---|
| Revolving Credit facility dated May 8, 2020, borrowings based upon eligible accounts receivable, subject to monthly borrowing base calculation, balance due on May 15, 2027. Effective interest rate for the first quarter of 2024 was 10.5% (1) | $— | $— | ||
| Term Loan 1 dated May 8, 2020, payable in equal monthly installments of principal, balance due on May 15, 2027. Effective interest rate for the first quarter of 2024 was 10.2% (1) | 107 | 213 | ||
| Term Loan 2 dated July 31, 2023, payable in equal monthly installments of principal, balance due on May 15, 2027. Effective interest rate for first quarter of 2024 was 9.5% (1) | 2,208 | 2,333 | ||
| Capital Line dated May 4, 2021, payable in equal monthly installments of principal, balance due on May 15, 2027. Effective interest rate for first quarter of 2024 was 9.0% (1) | 332 | 358 | ||
| Debt Issuance Costs | (158 | )(2) | (170 | )(2) |
| Notes Payable up to 2030, annual interest rate of 10.7% and 9.1%. | 57 | 14 | ||
| Total debt | 2,546 | 2,748 | ||
| Less current portion of long-term debt | 673 | 773 | ||
| Long-term debt | $1,873 | $1,975 | ||
| (1) | Our revolving credit facility is collateralized by our accounts receivable, and our term loans and capital line are collateralized by our property, plant, and equipment. |
| (2) | Aggregate unamortized debt issuance costs in connection with the Company’s credit facility, which consists of the revolving credit, Term loan 1, Term loan 2 and Capital Line, as applicable. |
Revolving Credit and Term Loan Agreement
The Company entered into a Second Amended and Restated Revolving Credit, Term Loan and Security Agreement, dated May 8, 2020 (“Loan Agreement”), with PNC National Association (“PNC” and “lender”), acting as agent and lender. The Loan Agreement, as amended from time to time, provides the Company with the following credit facility with a maturity date of May 15, 2027: (a) up to $12,500,000 revolving credit (“revolving credit”), with the maximum that the Company can borrow under the revolving credit based on a percentage of eligible receivables (as defined) at any one time reduced by outstanding standby letters of credit and borrowing reductions that the Company’s lender may impose from time to time; (b) a term loan (“Term Loan 1”) of approximately $1,742,000, requiring monthly installments of $35,547; (c) a term loan (“Term Loan 2”) of $2,500,000, requiring monthly installments of $41,667; and (d) a capital expenditure line (“Capital Line”) of up to $1,000,000 with advances on the line, subject to certain limitations, permitted for up to twelve months starting May 4, 2021 (the “Borrowing Period”). Amounts advanced under the Capital Line at the end of the Borrowing Period totaled approximately $524,000, requiring monthly installments of principal of approximately $8,700 plus interest, commencing June 1, 2022.
Pursuant to the Loan Agreement, as amended, payments of annual interest rates are as follows: (i) interest due on the revolving credit is at prime (8.50% at March 31, 2024) plus 2% or Secured Overnight Finance Rate (“SOFR”) (as defined in the Loan Agreement, as amended) plus 3.00% plus an SOFR Adjustment applicable for an interest period selected by the Company; (ii) interest due on each Term Loan 1 and the Capital Line is at prime plus 2.50% or SOFR plus 3.50% plus an SOFR Adjustment applicable for an interest period selected by the Company; and (iii) interest due on Term Loan 2 is at prime plus 3% or SOFR plus 4.00% plus an SOFR Adjustment applicable for an interest period selected by the Company. SOFR Adjustment rates of 0.10% and 0.15% are applicable for a one-month interest period and three-month period, respectively, that may be selected by the Company.
The Company agreed to pay PNC 1.0% of the total financing under the Loan Agreement, as amended, in the event the Company pays off its obligations on or before July 31, 2024, and 0.5% of the total financing if the Company pays off its obligations after July 31, 2024, to and including July 31, 2025. No early termination fee shall apply if the Company pays off its obligations under Loan Agreement, as amended, after July 31, 2025.
At March 31, 2024, the borrowing availability under the Company’s credit facility was approximately $2,379,000 which included our cash (deposited with the Company’s lender) and was based on our eligible receivables and is net of approximately $3,950,000 in outstanding standby letters of credit and net of a $750,000 indefinite reduction in borrowing availability imposed by the Company’s lender.
The Company’s credit facility under its Loan Agreement, as amended, with PNC contains certain financial covenants, along with customary representations and warranties. A breach of any of these financial covenants, unless waived by PNC, could result in a default under our credit facility allowing our lender to immediately require the repayment of all outstanding debt under our credit facility and terminate all commitments to extend further credit. The Company was not required to perform testing of its fixed charge coverage ratio (“FCCR”) requirement for the first quarter of 2024 pursuant to an amendment dated May 8, 2024, to the Company’s Loan Agreement, as amended (see “Note 15 – Subsequent Events – Credit Facility” for this amendment which removed the testing requirement of the FCCR for the first quarter of 2024, among other things). The Company met all of its other financial covenant requirements in the first quarter of 2024.
9. Commitments and Contingencies
Hazardous Waste
In connection with our waste management services, the Company processes hazardous, non-hazardous, low-level radioactive and mixed (containing both hazardous and low-level radioactive) waste, which the Company transports to its own, or other, facilities for destruction or disposal. As a result of disposing of hazardous substances, in the event any cleanup is required at the disposal site, the Company could be a potentially responsible party for the costs of the cleanup notwithstanding any absence of fault on our part.
Legal Matters
In the normal course of conducting our business, the Company may be involved in various litigation. The Company is not a party to any litigation or governmental proceeding which our management believes could result in any judgments or fines against us that would have a material adverse effect on our financial position, liquidity or results of future operations.
Tetra Tech EC, Inc. (“Tetra Tech”)
During July 2020, Tetra Tech EC, Inc. (“Tetra Tech”) filed a complaint in the U.S. District Court for the Northern District of California (the “Court”) against CH2M Hill, Inc. (“CH2M”) and four subcontractors of CH2M, including the Company (“Defendants”). The complaint alleges various claims, including a claim for negligence, negligent misrepresentation, equitable indemnification and related business claims against all Defendants related to alleged damages suffered by Tetra Tech in respect of certain draft reports prepared by Defendants at the request of the U.S. Navy as part of an investigation and review of certain whistleblower complaints about Tetra Tech’s environmental restoration at the Hunter’s Point Naval Shipyard in San Francisco.
CH2M was hired by the Navy in 2016 to review Tetra Tech’s work. CH2M subcontracted with environmental consulting and cleanup firms Battelle Memorial Institute, Cabrera Services, Inc., SC&A, Inc. and the Company to assist with the review, according to the complaint.
The Company’s insurance carrier is providing a defense on our behalf in connection with this lawsuit, subject to a $100,000 self-insured retention and the terms and limitations contained in the insurance policy.
The majority of Tetra Tech’s claims have been dismissed by the Court. Remaining claims include: (1) intentional interference with contractual relations; and (2) inducing a breach of contract. The Company continues to believe it has no liability exposure to Tetra Tech.
Perma-Fix Canada Inc. (“PF Canada”)
During the fourth quarter of 2021, PF Canada received a Notice of Termination (“NOT”) from Canadian Nuclear Laboratories, LTD. (“CNL”) on a Task Order Agreement (“TOA”) that PF Canada entered into with CNL in May 2019 for remediation work within Ontario, Canada (“Agreement”). The NOT was received after work under the TOA was substantially completed and work under the TOA has since been completed. CNL may terminate the TOA at any time for convenience. At year-end 2023, PF Canada had approximately $2,389,000 in outstanding receivables due from CNL as a result of work performed under the TOA. A settlement agreement was reached between PF Canada and CNL on the payment of the aforementioned amount by CNL, subject to certain conditions/terms precedents being met, including release of certain liens. The Company received a partial payment from CNL of the outstanding receivables during the first quarter of 2024. As of March 31, 2024, approximately $1,612,000 in outstanding receivables remain payable by CNL to PF Canada upon completion of the settlement conditions/terms, which the Company believes should occur by the end of 2024.
Insurance
The Company has a 25-year finite risk insurance policy entered into in June 2003 (“2003 Closure Policy”) with AIG Specialty Insurance Company (“AIG”), which provides financial assurance to the applicable states for our permitted facilities in the event of unforeseen closure. The 2003 Closure Policy, as amended, provides for a maximum allowable coverage of $28,177,000 which includes available capacity to allow for annual inflation and other performance and surety bond requirements. Total coverage under the 2003 Closure Policy, as amended, was $23,376,000 at March 31, 2024. As of March 31, 2024 and December 31, 2023, finite risk sinking funds contributed by the Company related to the 2003 Closure Policy which is included in other long term assets on the accompanying Condensed Consolidated Balance Sheets totaled $12,222,000 and $12,074,000, respectively, which included interest earned of $2,751,000 and $2,603,000 on the finite risk sinking funds as of March 31, 2024 and December 31, 2023, respectively. Interest income for the three months ended March 31, 2024, and 2023, was approximately $148,000 and $67,000, respectively. If the Company so elects, AIG is obligated to pay the Company an amount equal to 100% of the finite risk sinking fund account balance in return for complete release of liability from both us and any applicable regulatory agency using this policy as an instrument to comply with financial assurance requirements.
Letter of Credits and Bonding Requirements
From time to time, the Company is required to post standby letters of credit and various bonds to support contractual obligations to customers and other obligations, including facility closures. At March 31, 2024, the total amount of standby letters of credit outstanding was approximately $3,950,000 and the total amount of bonds outstanding was approximately $26,747,000.
10. Discontinued Operations
The Company’s discontinued operations consist of all our subsidiaries included in our previous Industrial Segment which encompasses subsidiaries divested in 2011 and prior and three previously closed locations.
The Company’s discontinued operations had net losses of $102,000 (net of tax benefit of $29,000) and $93,000 (net of tax benefit of $30,000) for the three months ended March 31, 2024, and 2023. The losses were primarily due to costs incurred in the administration and continued monitoring of our discontinued operations. The Company’s discontinued operations had no revenues for each of the periods noted above.
The following table presents the major class of assets of discontinued operations as of March 31, 2024, and December 31, 2023. No assets and liabilities were held for sale at each of the periods noted.
| March 31, | December 31, | |
|---|---|---|
| (Amounts in Thousands) | 2024 | 2023 |
| Current assets | ||
| Other assets | $13 | $13 |
| Total current assets | 13 | 13 |
| Long-term assets | ||
| Property, plant and equipment, net (1) | 81 | 81 |
| Total long-term assets | 81 | 81 |
| Total assets | $94 | $94 |
| Current liabilities | ||
| Accounts payable | $94 | $80 |
| Accrued expenses and other liabilities | 128 | 128 |
| Environmental liabilities | 16 | 61 |
| Total current liabilities | 238 | 269 |
| Long-term liabilities | ||
| Closure liabilities | 171 | 169 |
| Environmental liabilities | 784 | 784 |
| Total long-term liabilities | 955 | 953 |
| Total liabilities | $1,193 | $1,222 |
| (1) | net of accumulated depreciation of $10,000 for each period presented. |
11. Operating Segments
In accordance with ASC 280, “Segment Reporting”, the Company defines an operating segment as a business activity: (1) from which we may earn revenue and incur expenses; (2) whose operating results are regularly reviewed by the CODM to make decisions about resources to be allocated to the segment and assess its performance; and (3) for which discrete financial information is available.
Our reporting segments are defined below:
TREATMENT SEGMENT, which includes:
| - | nuclear, low-level radioactive, mixed waste (containing both hazardous and low-level radioactive constituents), hazardous and non-hazardous waste treatment, processing and disposal services primarily through four uniquely licensed and permitted treatment and storage facilities; and |
| - | R&D activities to identify, develop and implement innovative waste processing techniques for problematic waste streams. |
SERVICES SEGMENT, which includes:
| - | Technical services, which include: |
| o | professional radiological measurement and site survey of large government and commercial installations using advanced methods, technology and engineering; |
| o | integrated Occupational Safety and Health services including industrial hygiene (“IH”) assessments; hazardous materials surveys, e.g., exposure monitoring; lead and asbestos management/abatement oversight; indoor air quality evaluations; health risk and exposure assessments; health & safety plan/program development, compliance auditing and training services; and Occupational Safety and Health Administration (“OSHA”) citation assistance; |
| o | global technical services providing consulting, engineering, project management, waste management, environmental, and decontamination and decommissioning field, technical, and management personnel and services to commercial and government customers; and |
| o | on-site waste management services to commercial and governmental customers. |
| - | Nuclear services, which include: |
| o | technology-based services including engineering, decontamination and decommissioning (“D&D”), specialty services and construction, logistics, transportation, processing and disposal; |
| o | remediation of nuclear licensed and federal facilities and the remediation cleanup of nuclear legacy sites. Such services capability includes: project investigation; radiological engineering; partial and total plant D&D; facility decontamination, dismantling, demolition, and planning; site restoration; logistics; transportation; and emergency response; and |
| - | A company owned equipment calibration and maintenance laboratory that services, maintains, calibrates, and sources (i.e., rental) health physics, IH and customized nuclear, environmental, and occupational safety and health (“NEOSH”) instrumentation. |
Our reporting segments exclude our corporate headquarters and our discontinued operations (see “Note 10 – Discontinued Operations”) which do not generate revenues.
The table below presents certain financial information of our operating segments for the three months ended March 31, 2024, and 2023 (in thousands):
Segment Reporting for the Quarter Ended March 31, 2024
| Treatment · Services · Segments Total · Corporate (1) · Consolidated Total | ||||||
|---|---|---|---|---|---|---|
| Revenue from external customers | $8,709 | $4,908 | $13,617 | $— | $13,617 | |
| Intercompany revenues | 45 | 16 | 61 | — | — | |
| Gross loss | (52) | (568) | (620) | — | (620) | |
| Research and development | 218 | 28 | 246 | 50 | 296 | |
| Interest income | — | — | — | 174 | 174 | |
| Interest expense | (36) | — | (36) | (80) | (116) | |
| Interest expense-financing fees | — | — | — | (13) | (13) | |
| Depreciation and amortization | 366 | 44 | 410 | 21 | 431 | |
| Segment loss before income taxes | (1,371) | (1,388) | (2,759) | (1,655) | (4,414) | |
| Income tax benefit | (525) | (431) | (956) | — | (956) | |
| Segment loss | (846) | (957) | (1,803) | (1,655) | (3,458) | |
| Expenditures for segment assets | 160 | 84 | 244 | — | 244 | (2) |
Segment Reporting for the Quarter Ended March 31, 2023
| Treatment · Services · Segments Total · Corporate (1) · Consolidated Total | ||||||
|---|---|---|---|---|---|---|
| Revenue from external customers | $9,594 | $10,513 | $20,107 | $— | $20,107 | |
| Intercompany revenues | 204 | 19 | 223 | — | — | |
| Gross profit | 1,252 | 1,757 | 3,009 | — | 3,009 | |
| Research and development | 67 | 3 | 70 | 29 | 99 | |
| Interest income | — | — | — | 127 | 127 | |
| Interest expense | (22) | (1) | (23) | (30) | (53) | |
| Interest expense-financing fees | — | — | — | (20) | (20) | |
| Depreciation and amortization | 573 | 160 | 733 | 14 | 747 | |
| Segment income (loss) before income taxes | 157 | 943 | 1,100 | (1,622) | (522) | |
| Income tax benefit | (174) | (30) | (204) | — | (204) | |
| Segment income (loss) | 331 | 973 | 1,304 | (1,622) | (318) | |
| Expenditures for segment assets | 748 | — | 748 | — | 748 | (2) |
| (1) | Amounts reflect the activity for corporate headquarters not included in the segment information. |
| (2) | Net of financed amount of $44,000 and $50,000 for the three months ended March 31, 2024, and 2023, respectively. |
12. Income Taxes
The Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates, to determine its quarterly provision for income taxes.
The Company had income tax benefits of approximately $956,000 and $204,000 for continuing operations for the three months ended March 31, 2024, and 2023, respectively. The Company’s effective tax rate was approximately 21.7% and 39.1% for the three months ended March 31, 2024, and the corresponding period of 2023, respectively. The Company’s tax rates for the three months ended March 31, 2024, and 2023 were impacted by non-deductible expenses and state taxes.
The Organization for Economic Co-operation and Development (“OECD”) introduced Base Erosion and Profit Shifting (“BEPS”) Pillar 2 rules that impose a global minimum tax rate of 15% for multinational enterprises with annual global revenues exceeding €750 million. Numerous countries, including European Union member states, have enacted or are expected to enact legislation to be effective as early as January 1, 2024, with general implementation of a global minimum tax rate by January 1, 2025. The Company has evaluated the impact of these rules and currently believes they will not have any material impact on its financial results in 2024.
13. Variable Interest Entity (“VIE”)
On December 18, 2023, the joint venture (“JV”) where the Company and Campoverde Srl (“JV partner”) each owns 50% of the partnership, was awarded a multi-year contract valued up to approximately EUR 50 million by the European Commission (the “Contracting Authority”) for the treatment of radioactive waste from the Joint Research Center in Ispra, Work under this JV started in the first quarter of 2024 and has generated limited revenue in the first quarter of 2024. The scope of work under the initial phases of this contract will be performed predominately by our JV partner. Revenue generated by the Company under the initial phases is limited to project management support through 2025. The Company expects to generate an increase in revenue under this contract starting in 2026 when the waste treatment phases begin.
The Company determines whether joint ventures in which it has invested are VIEs at the start of each new venture and when a reconsideration event has occurred. A VIE is a legal entity that satisfies any of the following characteristics: (a) the legal entity does not have sufficient equity investment at risk; (b) the equity investors at risk as a group, lack the characteristics of a controlling financial interest; or (c) the legal entity is structured with disproportionate voting rights.
The Company consolidates a VIE if it is determined to be the primary beneficiary of the VIE. The primary beneficiary has both the power to direct the activities of the VIE that most significantly impact the entity’s economic performance and the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.
Based on the Company’s evaluation of this JV and the contractual terms of this arrangement, the Company determined that this JV is a VIE but the Company is not the primary beneficiary. Accordingly, no consolidation of this JV is required by the Company. No capital contributions have been or are expected to be made by either the Company or the JV partner under this JV.
14. Management Incentive Plans (“MIPs”)
On January 18, 2024, the Board (with Mr. Mark Duff and Dr. Louis Centofanti abstaining) and the Compensation and Stock Option Committee (the “Compensation Committee”) approved individual MIP for the calendar year 2024 for each of the Company’s executive officers. Each MIP is effective January 1, 2024 and applicable for year 2024. Each MIP provides guidelines for the calculation of annual cash incentive-based compensation, subject to Compensation Committee oversight and modification. The performance compensation under each of the MIPs is based upon meeting certain of the Company’s separate target objectives during 2024. The total potential target performance compensation payable ranges from 25% to 150% of the 2024 base salary for the Chief Executive Officer ($104,287 to $625,733),29% to 100% of the 2024 base salary for the Chief Financial Officer ($95,681 to $332,811),25% to 100% of the 2024 base salary for the Executive Vice President (“EVP”) of Strategic Initiatives ($69,337 to $277,346), and 25% to 100% ($71,317 to $285,267) of the 2024 base salary for the EVP of Waste Treatment Operations.
15. Subsequent Events
The Company evaluated subsequent events and transactions that occurred after the balance sheet date through May 9, 2024, the date that these consolidated financial statements were available to be issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the consolidated financial statements other than the below.
Credit Facility
On May 8, 2024, the Company entered into an amendment to its Loan Agreement, as amended, with its lender which provided the following, among other things:
| ● | removes the quarterly FCCR testing requirement for the first and second quarters of 2024; |
| ● | reinstates the quarterly FCCR testing requirement starting in the third quarter of 2024 and revises the methodology to be used in calculating the FCCR as follows (with no change to the minimum 1.15:1 ratio requirement): FCCR for the third quarter is to be determined based on financial results for the three-months period ending September 30, 2024; FCCR for the fourth quarter is to be determined based on financial results for the six-months period ending December 31, 2024; FCCR for the first quarter of 2025 is to be determined based on financial results for the nine-months period ending March 31, 2025; and FCCR for the second quarter of 2025 and each fiscal quarter thereafter is to be determined based on financial results for a trailing twelve-months period ending basis; |
| ● | requires maintenance of a daily minimum $2,250,000 in borrowing availability under the revolving credit through June 29, 2024, and a minimum of $3,000,000 in borrowing availability starting June 30, 2024, through June 29, 2025; and |
| ● | in the event the Company is able to achieve its minimum quarterly FCCR requirement utilizing its financial results based on a trailing twelve-months period starting with the quarter ending June 30, 2024, the maintenance of a daily minimum borrowing availability requirement of $3,000,000 as discussed above will be removed. Any subsequent fiscal quarter testing of the FCCR will revert back to a trailing twelve-months period method. |
In connection with the amendment, we paid our lender a fee of $25,000.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.